Results 81 to 90 of about 82,604 (202)

Mapping genetic interactions in cancer: a road to rational combination therapies. [PDF]

, 2019
The discovery of synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) inhibitors and BRCA genes, which are involved in homologous recombination, led to the approval of PARP inhibition as a monotherapy for patients with BRCA1/2 ...
Krogan, Nevan J, Tutuncuoglu, Beril
core  

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma. Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin [PDF]

, 2019
In recent years the introduction of target therapies with BRAF and MEK inhibitors (MAPKi) and of immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies have dramatically improved survival of metastatic melanoma patients. Despite these changes
Ascierto, Paolo Antonio, Bedogni, Barbara, Capone, Mariaelena, Ciliberto, Gennaro, Fattore, Luigi, Liguoro, Domenico, Madonna, Gabriele, Mallardo, Domenico, Malpicci, Debora, Mancini, Rita, Ruggiero, Ciro Francesco, Salvati, Valentina, Vanella, Vito   +12 more
core   +1 more source

Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses

Cell Reports, 2019
Summary: BRAF fusions are detected in numerous neoplasms, but their clinical management remains unresolved. We identified six melanoma lines harboring BRAF fusions representative of the clinical cases reported in the literature.
Thomas Botton, Eric Talevich, Vivek Kumar Mishra, Tongwu Zhang, A. Hunter Shain, Céline Berquet, Alexander Gagnon, Robert L. Judson, Robert Ballotti, Antoni Ribas, Meenhard Herlyn, Stéphane Rocchi, Kevin M. Brown, Nicholas K. Hayward, Iwei Yeh, Boris C. Bastian   +15 more
doaj   +1 more source

Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas [PDF]

, 2018
Pilocytic astrocytomas represent the most common glioma subtype in young patients and account for 5.4% of all gliomas. They are characterized by alterations in the RAS–MAP kinase pathway, the most frequent being a tandem duplication on chromosome 7q34 ...
Appay, Romain, Badiali, Manuela, Barets, Doriane, Colin, Carole, Figarella-Branger, Dominique, Fina, Frédéric, Giangaspero, Felice, Korshunov, Andrey, M. Pfister, Stefan, Macagno, Nicolas, Ordioni, Joanna, Padovani, Laëtitia, Scavarda, Didier, T. W. Jones, David   +13 more
core   +3 more sources

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. [PDF]

, 2016
Hundreds of genetically characterized cell lines are available for the discovery of genotype-specific cancer vulnerabilities. However, screening large numbers of compounds against large numbers of cell lines is currently impractical, and such experiments
A Basu, Alykhan F Shamji, Andrew Crenshaw, Andrew L Kung, Aristotle M Mannan, Aviad Tsherniak, Bang Wong, Barbara A Weir, Bradley R Taylor, C Ditchfield, Channing Yu, D Peck, E Comer, Griselda Metta Yvone, J Barretina, J Du, JM Korn, Joshua Z Gould, JP Koivunen, JT Lowe, Kenneth N Ross, KT Flaherty, LA Marcaurelle, Levi A Garraway, M Carmena, Melissa A Marton, MI Davis, Michael A Foley, Michelle A Palmer, MJ Garnett, MK Muellner, ML Sos, MW Karaman, NC Turner, OD Abaan, Pablo Tamayo, PD Andrews, SL Schreiber, SM Wilhelm, Stuart L Schreiber, SV Sharma, Todd R Golub, U McDermott, Wendy Winckler, XD Zhang, Yan-Ling Zhang   +45 more
core   +2 more sources

Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. [PDF]

, 2017
Recent genomic analyses have revealed substantial tumor heterogeneity across various cancers. However, it remains unclear whether and how genomic heterogeneity is constrained during tumor evolution.
Bivona, Trever G, Cai, Mei-Chun, Chen, Hong-Zhuan, Chen, Minjiang, Fu, Yujie, Gao, Wei-Qiang, Gu, Zhenyu, Jing, Ying, Ma, Pengfei, Shen, Ying, Wang, Mengzhao, Wu, Jie, Yan, Ying, Zhang, Shengzhe, Zhao, Xiaojing, Zhu, Liang, Zhuang, Guanglei   +16 more
core   +2 more sources

Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma

Case Reports in Oncological Medicine, 2017
Melanoma is a disease process which has been increasing in incidence over the past three decades and metastatic melanoma carries a poor prognosis. Through genetic studies of this disease, it has been determined that the BRAF V600 mutation plays a major ...
Brenen P. Swofford, Jade Homsi
doaj   +1 more source

BRAF-Inhibitor auch langfristig effektiv [PDF]

Im Focus Onkologie, 2012
Etwa 50 % der malignen Melanome weisen aktivierende Mutationen (V600-Mutationen) in der Serin-Threonin-Proteinkinase BRAF auf. Was kann der orale BRAF-Inhibitor Vemurafenib bei diesen Patienten leisten?
openaire   +1 more source

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells

Cancer Cell International, 2017
Background BRAF inhibitors are effective anticancer agents in BRAF-mutated melanomas. By contrast, evidences about sensitivity of thyroid carcinomas to BRAF inhibition are conflicting and it has been proposed that BRAF V600E thyroid carcinoma cells are ...
Tiziana Notarangelo, Lorenza Sisinni, Valentina Condelli, Matteo Landriscina   +3 more
doaj   +1 more source

Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers

ESMO Real World Data and Digital Oncology
Background: BRAF V600 mutations are the epitome of targeted therapy. However, not much is known about non-V600 mutations. Using the new data infrastructure of the Swiss Personalized Oncology project of the Swiss Personalized Health Network (SPHN), we ...
S. Pradervand, N. Freundler, B. Gosztonyi, L. Roncoroni, R. Achermann, T. Schwenk, G. de Fraipont, J. Garessus, S. Haefliger, A.B. Leichtle, M.K. Kiessling, T. Mueller-Focke, F.S. Krebs, V. Zoete, P. Tsantoulis, O. Michielin, C. Britschgi, A. Wicki   +17 more
doaj   +1 more source